More importantly, the prognostic impact of HDACs, together with our observation of the proposed interactions of HDAC isoforms with tumor cell proliferation and invasion, strongly suggests targeting class I HDACs might be an effective therapeutic strategy for HCC patients after LT. Here, HDAC9 is linked to hepatocellular carcinoma.